MedTrace Logo

The Use of Propranolol to Block Memory Reconsolidation in PTSD

NCT00611871 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2016-11-01

No results posted yet for this study

Summary

The purpose of this investigation is to see if propranolol will reduce the psychophysiological hyperactivation associated with memories of combat stress in Veterans with Posttraumatic Stress Disorder.

Conditions

  • Posttraumatic Stress Disorders

Interventions

DRUG

Propranolol

40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection

DRUG

Placebo

40mg placebo, followed 2 hrs after with 60mg placebo

Sponsors & Collaborators

  • John D. Dingell VA Medical Center

    collaborator FED

  • New York University

    collaborator OTHER

  • Wayne State University

    lead OTHER

Principal Investigators

  • Deane Aikins, PhD · Wayne State University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2015-08-31
Completion
2015-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00611871 on ClinicalTrials.gov